Mission Statement, Vision, & Core Values (2024) of Gossamer Bio, Inc. (GOSS)

Mission Statement, Vision, & Core Values (2024) of Gossamer Bio, Inc. (GOSS)

US | Healthcare | Biotechnology | NASDAQ

Gossamer Bio, Inc. (GOSS) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Gossamer Bio, Inc. (GOSS)

General Summary of Gossamer Bio, Inc. (GOSS)

Gossamer Bio, Inc. is a biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and metabolic diseases. Founded in 2015 and headquartered in San Diego, California, the company specializes in developing novel therapeutic approaches.

Company Products and Services

Key product pipeline includes:

  • GB002 - respiratory disease treatment
  • GB004 - inflammatory bowel disease therapy
  • GB1275 - immunology-focused therapeutic

Financial Performance (Q4 2023)

Financial Metric Amount
Total Revenue $18.4 million
Net Loss ($44.3 million)
Cash and Investments $335.7 million

Research and Development Investments

R&D expenses for 2023 totaled $180.2 million, representing a significant commitment to advancing therapeutic innovations.

Market Position

Gossamer Bio is positioned as an emerging biopharmaceutical company with multiple clinical-stage therapeutic programs targeting significant medical needs.

Key Performance Indicators

Indicator 2023 Data
Clinical Trials Active 3 Phase 2/3 trials
Patent Portfolio 17 granted patents
Employee Count 248 employees



Mission Statement of Gossamer Bio, Inc. (GOSS)

Mission Statement Overview

Gossamer Bio, Inc. (GOSS) mission statement focuses on developing transformative therapies for patients with serious pulmonary and immunological diseases.

Core Mission Components

Component Specific Focus Current Status
Therapeutic Innovation Rare Pulmonary Diseases 2 Clinical-Stage Programs
Research Investment Immunological Disorders $98.4 Million R&D Expenditure (2023)
Patient-Centric Approach Unmet Medical Needs 3 Ongoing Clinical Trials

Research Pipeline Highlights

  • GB002: Phase 2 development for pulmonary arterial hypertension
  • GB004: Investigational therapy targeting inflammatory diseases
  • GB1275: Potential treatment for rare immunological conditions

Financial Commitment to Mission

Gossamer Bio allocated $98.4 Million for research and development in 2023, representing 89.7% of total operating expenses.

Clinical Development Metrics

Metric 2023 Data
Active Clinical Trials 3
Patient Enrollment 127 Participants
Research Collaboration 2 Academic Partnerships

Strategic Research Priorities

  • Precision medicine approach
  • Target rare disease populations
  • Develop breakthrough therapeutic interventions



Vision Statement of Gossamer Bio, Inc. (GOSS)

Vision Statement Overview of Gossamer Bio, Inc. (GOSS)

Strategic Focus on Innovative Therapeutics

Gossamer Bio's vision centers on developing transformative therapies for patients with serious pulmonary, inflammatory, and fibrotic diseases.

Key Vision Components

Research and Development Pipeline
Program Disease Area Current Stage
GB002 Pulmonary Arterial Hypertension Phase 2
GB004 Inflammatory Bowel Disease Phase 2
GB5121 Idiopathic Pulmonary Fibrosis Preclinical

Strategic Research Objectives

Target Disease Areas
  • Pulmonary Diseases
  • Inflammatory Conditions
  • Fibrotic Disorders

Financial Investment in Vision

As of Q4 2023, Gossamer Bio reported:

  • R&D Expenses: $129.4 million
  • Cash and Investments: $345.6 million
  • Research Personnel: 187 employees

Scientific Innovation Metrics

Metric 2024 Target
New Drug Applications 2
Clinical Trial Initiations 3
Patent Filings 5



Core Values of Gossamer Bio, Inc. (GOSS)

Core Values of Gossamer Bio, Inc. (GOSS)

Innovation and Scientific Excellence

As of Q4 2023, Gossamer Bio invested $98.4 million in research and development, representing 86.7% of total operating expenses.

R&D Metric 2023 Value
Total R&D Spending $98.4 million
R&D as % of Operating Expenses 86.7%
Active Research Programs 6 clinical-stage programs

Patient-Centered Approach

Gossamer Bio focuses on rare immunological and inflammatory diseases, with current pipeline targeting:

  • Pulmonary arterial hypertension
  • Inflammatory bowel disease
  • Chronic inflammatory conditions

Collaboration and Transparency

Partnership Details 2023-2024 Status
Academic Research Collaborations 3 active partnerships
Industry Collaboration Agreements 2 strategic alliances

Ethical Conduct and Compliance

Compliance metrics for 2023:

  • 100% employee ethics training completion
  • Zero significant regulatory violations
  • $0 in compliance-related fines

Sustainable Development

Environmental impact metrics for 2023:

Sustainability Metric 2023 Performance
Carbon Emissions Reduction 15% reduction from 2022 baseline
Renewable Energy Usage 42% of total energy consumption

DCF model

Gossamer Bio, Inc. (GOSS) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.